Beihai Kangcheng-B(01228.HK): The injection of Vilasaine enzyme (Gorenin, CAN103) has been approved for listing in China.

Financial News APP reports that Beihai Kangcheng-B (01228.HK) has announced that injection of vilasinease (gorinane, CAN103) for injectable use has been granted market approval by the China National Medical Products Administration on May 15, 2025, for the treatment of Type I and Type III Gaucher's disease. The company holds global proprietary rights to develop and commercialize the product.